IBDEI3A4 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,55105,0)
 ;;=Z85.79^^256^2776^94
 ;;^UTILITY(U,$J,358.3,55105,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55105,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,55105,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,55105,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,55106,0)
 ;;=Z85.820^^256^2776^83
 ;;^UTILITY(U,$J,358.3,55106,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55106,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,55106,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,55106,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,55107,0)
 ;;=Z85.828^^256^2776^98
 ;;^UTILITY(U,$J,358.3,55107,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55107,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,55107,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,55107,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,55108,0)
 ;;=Z85.71^^256^2776^78
 ;;^UTILITY(U,$J,358.3,55108,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55108,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,55108,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,55108,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,55109,0)
 ;;=Z65.8^^256^2776^138
 ;;^UTILITY(U,$J,358.3,55109,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55109,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,55109,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,55109,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,55110,0)
 ;;=Z86.11^^256^2776^115
 ;;^UTILITY(U,$J,358.3,55110,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55110,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,55110,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,55110,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,55111,0)
 ;;=Z86.13^^256^2776^82
 ;;^UTILITY(U,$J,358.3,55111,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55111,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,55111,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,55111,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,55112,0)
 ;;=Z86.73^^256^2776^112
 ;;^UTILITY(U,$J,358.3,55112,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55112,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,55112,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,55112,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,55113,0)
 ;;=Z86.79^^256^2776^75
 ;;^UTILITY(U,$J,358.3,55113,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55113,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,55113,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,55113,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,55114,0)
 ;;=Z91.040^^256^2776^64
 ;;^UTILITY(U,$J,358.3,55114,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55114,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,55114,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,55114,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,55115,0)
 ;;=Z98.89^^256^2776^120
 ;;^UTILITY(U,$J,358.3,55115,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55115,1,3,0)
 ;;=3^Postprocedural States/Hx of Surgery NEC
 ;;^UTILITY(U,$J,358.3,55115,1,4,0)
 ;;=4^Z98.89
 ;;^UTILITY(U,$J,358.3,55115,2)
 ;;=^5063754
 ;;^UTILITY(U,$J,358.3,55116,0)
 ;;=Z92.3^^256^2776^79
 ;;^UTILITY(U,$J,358.3,55116,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55116,1,3,0)
 ;;=3^Personal Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,55116,1,4,0)
 ;;=4^Z92.3
 ;;^UTILITY(U,$J,358.3,55116,2)
 ;;=^5063637
 ;;^UTILITY(U,$J,358.3,55117,0)
 ;;=Z91.120^^256^2776^60
 ;;^UTILITY(U,$J,358.3,55117,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,55117,1,3,0)
 ;;=3^Intentional Underdose of Meds d/t Financial Hardship
